Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Studying the course of Covid-19 by a recursive delay approach

Matthias Kreck, View ORCID ProfileErhard Scholz
doi: https://doi.org/10.1101/2021.01.18.21250012
Matthias Kreck
†Mathematisches Institut der Universität Bonn and Mathematisches Institut der Universit ät Frankfurt, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kreck@math.uni-bonn.de
Erhard Scholz
‡University of Wuppertal, Faculty of Math./Natural Sciences, and Interdisciplinary Centre for History and Philosophy of Science,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erhard Scholz
  • For correspondence: escholz@uni-wuppertal.de scholz@math.uni-wuppertal.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

In an earlier paper we proposed a recursive model for epidemics; in the present paper we generalize this model to include the asymptomatic or unrecorded symptomatic people, which we call dark people (dark sector). We call this the SEPARd-model. A delay differential equation version of the model is added; it allows a better comparison to other models. We carry this out by a comparison with the classical SIR model and indicate why we believe that the SEPARd model may work better for Covid-19 than other approaches.

In the second part of the paper we explain how to deal with the data provided by the JHU, in particular we explain how to derive central model parameters from the data. Other parameters, like the size of the dark sector, are less accessible and have to be estimated more roughly, at best by results of representative serological studies which are accessible, however, only for a few countries. We start our country studies with Switzerland where such data are available. Then we apply the model to a collection of other countries, three European ones (Germany, France, Sweden), the three most stricken countries from three other continents (USA, Brazil, India). Finally we show that even the aggregated world data can be well represented by our approach.

At the end of the paper we discuss the use of the model. Perhaps the most striking application is that it allows a quantitative analysis of the influence of the time until people are sent to quarantine or hospital. This suggests that imposing means to shorten this time is a powerful tool to flatten the curves.

Competing Interest Statement

No competing interests.

Funding Statement

No external funding for the project

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Does not apply

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Corrrection of formulas pp. 5, 6, 7, 20, general case of dark model, p_c \neq p_d included, tautological model for eta_7 added.

Data Availability

The model works with data publicly available under https://data.humdata.org/dataset/novel-coronavirus-2019-ncov-cases

https://data.humdata.org/dataset/novel-coronavirus-2019-ncov-cases

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted February 27, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Studying the course of Covid-19 by a recursive delay approach
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Studying the course of Covid-19 by a recursive delay approach
Matthias Kreck, Erhard Scholz
medRxiv 2021.01.18.21250012; doi: https://doi.org/10.1101/2021.01.18.21250012
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Studying the course of Covid-19 by a recursive delay approach
Matthias Kreck, Erhard Scholz
medRxiv 2021.01.18.21250012; doi: https://doi.org/10.1101/2021.01.18.21250012

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (180)
  • Allergy and Immunology (435)
  • Anesthesia (99)
  • Cardiovascular Medicine (949)
  • Dentistry and Oral Medicine (178)
  • Dermatology (111)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (423)
  • Epidemiology (9018)
  • Forensic Medicine (4)
  • Gastroenterology (422)
  • Genetic and Genomic Medicine (1964)
  • Geriatric Medicine (191)
  • Health Economics (405)
  • Health Informatics (1333)
  • Health Policy (662)
  • Health Systems and Quality Improvement (522)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10832)
  • Intensive Care and Critical Care Medicine (576)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (223)
  • Neurology (1842)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (358)
  • Occupational and Environmental Health (470)
  • Oncology (1006)
  • Ophthalmology (299)
  • Orthopedics (111)
  • Otolaryngology (184)
  • Pain Medicine (126)
  • Palliative Medicine (45)
  • Pathology (267)
  • Pediatrics (583)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1910)
  • Public and Global Health (4137)
  • Radiology and Imaging (678)
  • Rehabilitation Medicine and Physical Therapy (370)
  • Respiratory Medicine (551)
  • Rheumatology (226)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (110)
  • Urology (82)